In The News: Chambers-Grundy Center for Transformative Neuroscience
Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.
The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.
It’s called the Chambers-Grundy Center for Transformative Neuroscience at 51ԹϺ, and the adjective in the name says it all.
Despite projections implying that the clinical use of aducanumab (Aduhelm; Biogen), the first drug approved for the treatment of Alzheimer disease (AD), would be widespread by this point, financial reports have indicated that the clinical use of the therapy is far below expectations.
reMYND NV, a clinical stage company, is pleased to announce that it has initiated the multiple-ascending-dose (MAD) phase of its Alzheimer’s program after observing no compound-related ReS19-T adverse events so far in the 58 healthy volunteers in the single-ascending dose (SAD) phase.
Researchers looking for a pre-approved drug that can be reused to treat Alzheimer’s disease have found promising signs of efficacy in a 50-year-old generic drug commonly used as a diuretic.
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.
A generic drug used widely to treat swelling associated with hypertension and heart failure showed hints in early research that it may also prevent the devastating brain damage of Alzheimer’s disease, a surprising twist that suggests scientists have a lot more to learn about the root cause of the neurodegenerative condition.
Alpha Cognition Inc., a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today announced the formation of a Scientific Advisory Board comprised of industry leaders in neurology and psychiatry, chaired by James E. Galvin, MD, MPH.
Optimistic about the drug’s efficacy, the company has initiated its submission for accelerated FDA approval.
Approval of aducanumab will herald a new era in Alzheimer’s disease care and research.
The Food and Drug Administration’s controversial June 7 approval of aducanumab (Aduhelm) means that for the first time in 18 years, Alzheimer’s patients have a new treatment option.